| Literature DB >> 23410245 |
Li-Yeh Chuang1, Hsueh-Wei Chang, Ming-Cheng Lin, Cheng-Hong Yang.
Abstract
BACKGROUND: Single nucleotide polymorphisms (SNPs) in genes derived from distinct pathways are associated with a breast cancer risk. Identifying possible SNP-SNP interactions in genome-wide case-control studies is an important task when investigating genetic factors that influence common complex traits; the effects of SNP-SNP interaction need to be characterized. Furthermore, observations of the complex interplay (interactions) between SNPs for high-dimensional combinations are still computationally and methodologically challenging. An improved branch and bound algorithm with feature selection (IBBFS) is introduced to identify SNP combinations with a maximal difference of allele frequencies between the case and control groups in breast cancer, i.e., the high/low risk combinations of SNPs.Entities:
Year: 2013 PMID: 23410245 PMCID: PMC3626712 DOI: 10.1186/2043-9113-3-4
Source DB: PubMed Journal: J Clin Bioinforma ISSN: 2043-9113
Estimated best combinations of two SNPs on the occurrence of breast cancer
| High-risk | Two SNPs | Other | 330/209 | | | | | | |
| SNPs (4, 7) | 2-3 | 4/11 | 0.616 | 0.050 | 0.988 | 0.551 | 4.342 (1.259-16.394) | 0.013 | |
| (Diff. = 7) | |||||||||
| Two SNPs | Other | 327/209 | | | | | | | |
| SNPs (4, 6) | 3-2 | 7/11 | 0.610 | 0.050 | 0.979 | 0.546 | 2.459 (0.867-7.143) | 0.084 | |
| (Diff. = 4) | |||||||||
| Two SNPs | Other | 289/172 | | | | | | | |
| SNPs (3, 5) | 2-1 | 45/48 | 0.608 | 0.218 | 0.865 | 0.564 | 1.792 (1.118-2.875) | 0.014 | |
| (Diff. = 3) | |||||||||
| Low-risk | Two SNPs | Other | 197/151 | | | | | | |
| SNPs (3, 4) | 1-1 | 137/69 | 0.480 | 0.314 | 0.589 | 0.461 | 0.657 (0.452-0.955) | 0.025 | |
| (Diff. = 68) | |||||||||
| Two SNPs | Other | 226/174 | | | | | | | |
| SNPs (3, 7) | 1-2 | 108/46 | 0.491 | 0.209 | 0.676 | 0.459 | 0.553 (0.364-0.839) | 0.004 | |
| (Diff. = 62) | |||||||||
| Two SNPs | Other | 223/168 | | | | | | | |
| SNPs (1, 3) | 2-1 | 111/52 | 0.496 | 0.236 | 0.668 | 0.467 | 0.622 (0.415-0.931) | 0.017 | |
| (Diff. = 59) | |||||||||
NOTE - Other: The reference group, indicating the union of all other possible two to seven SNP combinations; N.E: Not estimable; CC: Correct; SN: Sensitivity; SP: Specificity.
Estimated best combinations of SNPs on the occurrence of breast cancer in the high risk group
| Two SNPs | Other | 330/209 | | | | | | |
| SNPs (4, 7) | 2-3 | 4/11 | 0.615 | 0.050 | 0.988 | 0.551 | 4.342 (1.259-16.934) | 0.013 |
| (Diff. = 7) | ||||||||
| Three SNPs | Other | 314/191 | | | | | | |
| SNPs (3, 5, 6) | 2-1-1 | 20/29 | 0.619 | 0.132 | 0.940 | 0.564 | 2.384 (1.263-4.518) | 0.005 |
| (Diff. = 9) | ||||||||
| Four SNPs | Other | 325/203 | | | | | | |
| SNPs (3, 4, 5, 6) | 2-1-1-1 | 9/17 | 0.617 | 0.077 | 0.973 | 0.556 | 3.024 (1.246-7.491) | 0.008 |
| (Diff. = 8) | ||||||||
| Five SNPs | Other | 329/210 | | | | | | |
| SNPs (1, 3, 4, 5, 6) | 1-2-1-1-1 | 5/10 | 0.612 | 0.045 | 0.985 | 0.547 | 3.133 (0.969-10.680) | 0.031 |
| (Diff. = 5) | ||||||||
| Six SNPs | Other | 332/214 | | | | | | |
| SNPs (1, 2, 3, 5, 6, 7) | 1-2-2-1-1-2 | 0/4 | 0.610 | 0.018 | 1.000 | N.E | ||
| (Diff. = 4) | ||||||||
| Seven SNPs | Other | 333/216 | | | | | | |
| SNPs (1, 2, 3, 4, 5, 6, 7) | 2-2-2-1-1-1-1 | 1/4 | 0.608 | 0.014 | 0.997 | 0.540 | 6.167 (0.648-145.871) | 0.084 |
| (Diff. = 3) |
NOTE - Other: The reference group, indicating the union of all other possible two to seven SNP combinations; N.E: Not estimable; CC: Correct; SN: Sensitivity; SP: Specificity.
Estimated best combinations of SNPs on the occurrence of breast cancer in the low risk group
| Two SNPs | Other | 197/151 | | | | | | |
| SNPs (3, 4) | 1-1 | 137/69 | 0.480 | 0.314 | 0.600 | 0.465 | 0.657 (0.452-0.955) | 0.025 |
| (Diff. = 68) | ||||||||
| Three SNPs | Other | 260/189 | | | | | | |
| SNPs (1, 3, 5) | 2-1-1 | 74/31 | 0.525 | 0.141 | 0.778 | 0.481 | 0.576 (0.355-0.934) | 0.020 |
| (Diff. = 43) | ||||||||
| Four SNPs | Other | 294/207 | | | | | | |
| SNPs (1, 2, 3, 4) | 2-2-1-1 | 40/13 | 0.554 | 0.059 | 0.880 | 0.498 | 0.462 (0.228-0.919) | 0.018 |
| (Diff. = 27) | ||||||||
| Five SNPs | Other | 310/215 | | | | | | |
| SNPs (1, 2, 3, 4, 5) | 2-2-1-1-1 | 24/5 | 0.569 | 0.023 | 0.928 | 0.507 | 0.300 (0.099-0.846) | 0.011 |
| (Diff. = 19) | ||||||||
| Six SNPs | Other | 323/218 | | | | | | |
| SNPs (1, 2, 3, 4, 5, 6) | 2-2-1-1-1-2 | 11/2 | 0.587 | 0.009 | 0.967 | 0.521 | 0.269 (0.041-1.301) | 0.070 |
| (Diff. = 9) | ||||||||
| Seven SNPs | Other | 325/219 | | | | | | |
| SNPs (1, 2, 3, 4, 5, 6, 7) | 2-2-1-1-1-2-1 | 9/1 | 0.588 | 0.005 | 0.973 | 0.522 | 0.165 (0.008-1.277) | 0.098 |
| (Diff. = 8) |
NOTE - Other: The reference group, indicating the union of all other possible two to seven SNP combinations; N.E: Not estimable; CC: Correct; SN: Sensitivity; SP: Specificity.
Odds ratio () (95% CI) (-value) for SNP interactions in SNP (4, 7) combinations
| | |||||
|---|---|---|---|---|---|
| TT | 1.047 | 1.163 | 1.685 | ||
| Genotypes (Y) | 0.709-1.546 | 0.763-1.773 | 0.706-4.030 | ||
| 0.849 | 0.471 | 0.214 | |||
| (66/97) | (54/73) | (13/12) | |||
| CT | 0.460 | 0.823 | 0.499 | ||
| 0.265-0.793 | 0.503-1.341 | 0.106-2.034 | |||
| 0.003 | 0.484 | 0.379 | |||
| (22/65) | (33/59) | (3/9) | |||
| CC | 0.811 | 4.342 | N.E | ||
| 0.288-2.221 | 1.259-16.394 | | |||
| 0.817 | 0.013 | | |||
| (7/13) | (11/4) | ||||
NOTE - *:SNPs (4, 7) pair with its corresponding genotypes CXCL12-rs1801157- genotype X and KITLG-rs10506957-genotype Y; a: OR in reference to the other group (1.000); CI: Confidence Interval; Ca.: case; Co.: control; N.E: Not estimable.
Figure 1SNPs (4, 7) with their corresponding genotypes CXCL12-rs1801157 and KITLG-rs10506957.
Odds ratio () (95% CI) (-value) for SNP interactions in SNP (3, 4) combinations
| | |||||
|---|---|---|---|---|---|
| GG | 0.657 | 1.557 | 1.528 | ||
| Genotypes (Y) | 0.459-0.940 | 0.936-2.590 | 0.414-5.636 | ||
| 0.025 | 0.110 | 0.719 | |||
| (69/137) | (33/34) | (4/4) | |||
| AG | 1.092 | 1.222 | 1.012 | ||
| 0.757-1.576 | 0.712-2.098 | 0.201-5.111 | |||
| 0.639 | 0.484 | 1.000 | |||
| (70/100) | (26/33) | (2/3) | |||
| AA | 1.076 | 1.012 | N.E | ||
| 0.511-2.266 | 0.303-3.382 | | |||
| 0.848 | 1.000 | | |||
| (12/17) | (4/6) | ||||
NOTE - *: SNPs (3, 4) pair with its corresponding genotypes CXCR4-rs2228014-genotype X and KITLG-rs10506957-genotype Y; a: OR in reference to the other group (1.000); CI: Confidence Interval; Ca.: case; Co.: control; N.E: Not estimable.
Figure 2SNPs (3, 4) with their corresponding genotypes CXCR4-rs2228014 and CXCL12-rs1801157.
The representative difference of the [Control-Breast Cancer] occurrence value by PSO and GA
| SNPs (3,4) | (1–1) | 137/69 | 68 | 7 | 7 |
| SNPs (3,7) | (1–2) | 108/46 | 62 | 2 | 1 |
| SNPs (3,5) | (1–1) | 162/103 | 59 | 1 | 2 |
NOTE - SNPs (3, 4) represents the combination of SNP3-SNP4, i.e., rs2228014 - rs1801157. Other combinations follow the same pattern. SNP Genotype (1–1) represent the SNP genotype (CC – GG) combinations. PSO: particle swarm optimization; GA: genetic algorithm.
Baseline characteristics of breast cancer cases and controls
| 1. rs12812942 | 12 | 1-AA | 174/128 | | | | | | |
| (CD4) | | 2-AT | 141/76 | 0.482 | 0.372 | 0.552 | 0.469 | 0.733 (0.503-1.068) | 0.10 |
| | | 3-TT | 19/16 | 0.564 | 0.111 | 0.902 | 0.526 | 1.145 (0.536-2.438) | 0.72 |
| 2. rs3136685 | 17 | 1-GG | 107/77 | | | | | | |
| (CCR7) | | 2-AG | 180/114 | 0.462 | 0.587 | 0.373 | 0.474 | 0.880 (0.594-1.304) | 0.57 |
| | | 3-AA | 47/29 | 0.523 | 0.274 | 0.695 | 0.357 | 0.857 (0.478-1.536) | 0.68 |
| 3. rs2228014 | 2 | 1-CC | 254/151 | | | | | | |
| (CXCR4) | | 2-CT | 73/63 | 0.586 | 0.294 | 0.777 | 0.552 | 1.452 (0.962-2.191) | 0.07 |
| | | 3-TT | 7/6 | 0.622 | 0.382 | 0.973 | 0.659 | 1.442 (0.421-4.880) | 0.57 |
| 4. rs1801157 | 10 | 1-GG | 175/106 | | | | | | |
| (CXCL12) | | 2-AG | 136/98 | 0.530 | 0.480 | 0.562 | 0.524 | 1.189 (0.822-1.723) | 0.37 |
| | | 3-AA | 23/16 | 0.597 | 0.131 | 0.884 | 0.537 | 1.149 (0.550-2.387) | 0.73 |
| 5. rs3025039 | 6 | 1-CC | 211/155 | | | | | | |
| (VEGF) | | 2-CT | 117/59 | 0.498 | 0.276 | 0.643 | 0.472 | 0.687 (0.463-1.016) | 0.05 |
| | | 3-TT | 6/6 | 0.574 | 0.037 | 0.972 | 0.528 | 1.361 (0.381-4.870) | 0.77 |
| 6. rs2287074 | 16 | 1-GG | 164/113 | | | | | | |
| (MMP2) | | 2-AG | 139/93 | 0.505 | 0.451 | 0.541 | 0.499 | 0.971 (0.670-1.408) | 0.93 |
| | | 3-AA | 31/14 | 0.553 | 0.110 | 0.841 | 0.510 | 0.655 (0.316-1.347) | 0.25 |
| 7. rs10506957 | 12 | 1-TT | 182/133 | | | | | | |
| (KITLG) | | 2-CT | 133/69 | 0.486 | 0.342 | 0.578 | 0.469 | 0.709 (0.484-1.042) | 0.08 |
| 3-CC | 19/18 | 0.568 | 0.119 | 0.905 | 0.531 | 1.296 (0.622-2.700) | 0.08 | ||
NOTE - Chr: Chromosome; Control no: number of control; Case no: number of case; CC: Correct; SN: Sensitivity; SP: Specificity.